United States

Pain Therapeutics Inc (PTIE.OQ)

PTIE.OQ on NASDAQ Stock Exchange Global Select Market

24 May 2016
Change (% chg)

-- (--)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low


Chart for PTIE.OQ


Pain Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on drug development efforts on disorders of the nervous system, such as chronic pain. The Company's lead drug candidate, REMOXY, is an abuse-deterrent, oral formulation of oxycodone (CII). The Company's other products is FENROCK. REMOXY is a... (more)


Beta: 1.29
Market Cap(Mil.): $106.13
Shares Outstanding(Mil.): 46.14
Dividend: --
Yield (%): --


  PTIE.OQ Industry Sector
P/E (TTM): -- 41.86 35.43
EPS (TTM): -0.38 -- --
ROI: -54.48 -6.03 13.09
ROE: -54.48 -6.57 14.22

BRIEF-Pain Therapeutics reports Q1 loss per share $0.13

* Q1 loss per share $0.13 Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)

May 05 2016

BRIEF-Durect licensee, Pain Therapeutics resubmitts NDA for Remoxy to U.S. FDA

* Durect announces resubmission of Remoxy New Drug Application to the U.S. Food and Drug Administration

Mar 29 2016

BRIEF-Pain Therapeutics resubmits REMOXY new drug application to U.S. FDA

* Pain Therapeutics resubmits REMOXY new drug application to the U.S. Food and drug administration

Mar 29 2016

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Jefferson Research
Provider : GlobalData
Provider : ValuEngine, Inc.
Provider : S&P Capital IQ Quantitative Report
Provider : Pechala's Reports

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.